Delhi HC restricts supply of Zydus cancer drug Ikra in patent dispute

Litigation LossRegulatory & Legal

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.5%1-day move

₹1133.80

prior close

₹1145.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.6-0.8-0.6-0.7+1.5+0.9+1.3+1.1-0.8-2.1————

Up moveDown movePending

AI summary

The Delhi High Court has temporarily restricted Zydus Lifesciences from supplying its cancer drug Ikra amid a patent dispute with AbbVie. The stock exchange has sought clarification from the company on this news development. The company response is awaited. The restriction is interim and linked to alleged patent infringement claims filed by AbbVie against the product.

Likely market impact

Negative near-term - court order limits sales of cancer drug Ikra until the patent dispute with AbbVie is resolved.